Source: Anthropic has acquired Coefficient Bio, which was developing a platform that enables AI to run biotech tasks such as planning drug research, for ~$400M (The Information)
Why it matters: Anthropic's acquisition of Coefficient Bio for ~$400M directly integrates AI into drug research.
- Anthropic has acquired Coefficient Bio, a startup developing an AI platform for biotech tasks like planning drug research, for an estimated $400 million (The Information).
- Coefficient Bio was specifically focused on enabling AI to run complex biotech operations, streamlining drug discovery and research (The Information).
- The Hacker News covers the broader context of trusted open-source reports, which, while not directly about this acquisition, highlights the increasing scrutiny and importance of underlying technological frameworks in AI and biotech.
AI giant Anthropic has reportedly acquired biotech startup Coefficient Bio for approximately $400 million, a move that integrates AI's capabilities directly into drug research and biotech task planning. This acquisition, as detailed by The Information, signifies a major push into applying advanced AI platforms to complex scientific domains, though other sources like The Hacker News focus more broadly on open-source security in tech.
